Eli Lilly and Co
This under-the-radar biotech could be the next way to play the obesity drug boom
The lucrative market for obesity drugs is dominated by two players right now, but Structure Therapeutics has the potential to enter the category with an oral GLP-1 medication, according to Piper Sandler. Analyst Yasmeen Rahimi initiated coverage of the clinical stage drugmaker with an overweight rating on Thursday, and set a $58 price target, which […]
Read More
Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020. Mike Blake | Reuters An Eli Lilly experimental drug helped patients lose about 26% of their weight on average following extended use or intensive lifestyle changes, according to results from two studies released Thursday. It’s the […]
Read More
UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images U.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk‘s Wegovy and Ozempic after some patients who took the treatments […]
Read More
Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images Danish pharmaceutical giant Novo Nordisk is set to launch its hugely popular Wegovy obesity drug in Germany this month, but it could be some time before […]
Read More
Morgan Stanley sees profound shift in diabetes treatment boosting opportunity for weight-loss drugs
Morgan Stanley analysts said they are seeing a profound shift in the way diabetes is being treated, with doctors intensifying the focus on weight management, which is accelerating the uptake of GLP-1 medications. What’s more, the analysts anticipate that over the next 24 months, this weight-centric approach will start to spread to other health complications […]
Read More
Medicare proposes removing limit on PET scans used to help diagnose Alzheimer’s disease
Jay Reinstein, who suffers from Alzheimer’s, sits on a bed after receiving a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty Images Medicare plans to expand its coverage of PET scans that are used to help diagnose Alzheimer’s disease, a […]
Read More
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer’s treatment, donanemab, and expects the agency to make a decision by the end of the year. Eli Lilly is […]
Read More
What investors need to know about weight loss medicines and suicide risk
Investors would be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week. Prior attempts to treat overweight or obese patients with medications were often plagued with side effects and drug recalls. Those earlier medications often didn’t seem like the results […]
Read More
Shares generating the most important moves midday: UnitedHealth, JPMorgan Chase, Microsoft, JetBlue and far more
A UnitedHealth Group health insurance plan card is observed in a wallet, Oct.14, 2019. Lucy Nicholson | Reuters Check out out the corporations creating headlines in midday trading. JPMorgan Chase — Shares fell somewhat even immediately after the bank documented more robust-than-predicted outcomes for the next quarter, as it benefited from increased interest costs and […]
Read More
Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Friday said it will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to boost the pharmaceutical giant’s weight loss treatment portfolio. Eli Lilly agreed to pay Versanis shareholders in […]
Read More